DNA methylation as a molecular biomarker in gastric cancer

Epigenomics

Volumn 7, Issue 3, 2015, Pages 475-486

  Tahara, Tomomitsu ^a   Arisawa, Tomiyasu ^b  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

chromatin remodeling; CIMP; CpG island methylator phenotype; DNA methylation; epigenetics; gastric cancer; Helicobacter pylori; molecular biomarker

Indexed keywords

APC PROTEIN; DEATH ASSOCIATED PROTEIN KINASE; FIZZY RELATED PROTEIN; GLUTATHIONE TRANSFERASE P1; PROTEIN P16; TRANSCRIPTION FACTOR RUNX3; TUMOR MARKER; GENETIC MARKER;

CANCER SURVIVAL; CPG ISLAND; CPG ISLAND METHYLATOR PHENOTYPE; DNA METHYLATION; EPIGENETIC REPRESSION; EPIGENETICS; HELICOBACTER INFECTION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; STOMACH CANCER; STOMACH CARCINOGENESIS; STOMACH MUCOSA; TUMOR SUPPRESSOR GENE; GASTRIC MUCOSA; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETIC MARKER; GENETICS; HELICOBACTER PYLORI; HUMAN; METABOLISM; MICROBIOLOGY; STOMACH NEOPLASMS;

HELICOBACTER PYLORI;

CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; GASTRIC MUCOSA; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84931360022     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.15.4     Document Type: Review

References (91)

1. Ferlay J, Bray F, Parkin DM, Pisani P (Eds). Gobocan 2000: Cancer Incidence and Mortality Worldwide (IARC Cancer Bases No. 5). Lyon: IARC Press (2001).
2. Lau M, Le A, El-Serag HB. Noncardia gastric adenocarcinoma remains an important and deadly cancer in the United States: secular trends in incidence and survival. Am. J. Gastroenterol. 101(11), 2485-2492 (2006).
3. Nashimoto A, Akazawa K, Isobe Y et al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer 16(1), 1-27 (2013).
4. Uemura N, Okamoto S, Yamamoto S et al. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 345(11), 784-789 (2001).
5. Vogelstein B, Papadopoulos N, Velculescu VE et al. Cancer genome landscapes. Science 339, 1546-1558 (2013).
6. Ushijima T, Asada K. Aberrant DNA methylation in contrast with mutations. Cancer Sci. 101, 300-305 (2010).
7. Calcagno DQ, Gigek CO, Chen ES, Burbano RR, Smith MA. DNA and histone methylation in gastric carcinogenesis. World J. Gastroenterol. 19, 1182-1192 (2013).
8. Tsai KW, Wu CW, Hu LY et al. Epigenetic regulation of miR-34b and miR-129 expression in gastric cancer. Int. J. Cancer 129, 2600-2610 (2011).
9. Ziogas D, Roukos D. Epigenetics in gastric cancer: challenges for clinical implications. Ann. Surg. Oncol. 16, 2077-2078 (2009).
10. Wolffe AP, Matzke MA. Epigenetics: regulation through repression. Science 286, 481-486 (1999).
11. Gama-Sosa MA, Slagel VA, Trewyn RW et al. The 5-methylcytosine contentof DNA from human tumors. Nucleic Acids Res. 11, 6883-6894 (1983).
12. Dunn BK. Hypomethylation: one side of a larger picture. Ann. NY Acad. Sci. 983, 28-42 (2003).
13. Esteller M, Herman JG. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J. Pathol. 196, 1-7 (2002).
14. Eden A, Gaudet F, Waghmare A, Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300, 455 (2003).
15. Gaudet F, Hodgson JG, Eden A et al. Induction of tumors in mice by genomic hypomethylation. Science 300, 489-492 (2003).
16. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 21, 5400-5413 (2002).
17. Ehrlich M. DNA hypomethylation, cancer, the immunodeficiency, centromeric region instability, facial anomalies syndrome and chromosomal rearrangements. J. Nutr. 132, 2424S-2429S (2002).
18. Berman BP, Weisenberger DJ, Aman JF et al. Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. Nat. Genet. 44(1), 40-46 (2011).
19. Timp W, Feinberg AP. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat. Rev. Cancer 13(7), 497-510 (2013).
20. Jones PA, Baylin SB. The epigenomics of cancer. Cell 128(4), 683-692 (2007).
21. Toyota M, Issa JP. Epigenetic changes in solid and hematopoietic tumors. Semin. Oncol. 32(5), 521-530 (2005).
22. Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. Nat. Rev. Cancer 5(3), 223-231 (2005).
23. Bird AP, Wolffe AP. Methylation-induced repression-belts, braces, and chromatin. Cell 99(5), 451-454 (1999).
24. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat. Genet. 21(2), 163-7 (1999).
25. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc. Natl Acad. Sci. USA 96(15), 8681-8686 (1999).
26. Kusano M, Toyota M, Suzuki H et al. Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus. Cancer 106(7), 1467-1479 (2006).
27. Cancer Genome Atlas Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513(7517), 202-209 (2014).
28. Maekita T, Nakazawa K, Mihara M et al. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin. Cancer Res. 12(3 Pt 1), 989-995 (2006).
29. Tahara T, Arisawa T, Shibata T et al. Increased number of methylated CpG islands correlates with Helicobacter pylori infection, histological and serological severity of chronic gastritis. Eur. J. Gastroenterol. Hepatol. 21(6), 613-619 (2009).
30. Tahara T, Shibata T, Nakamura M et al. Increased number of CpG island hypermethylation in tumor suppressor genes of non-neoplastic gastric mucosa correlates with higher risk of gastric cancer. Digestion 82(1), 27-36 (2010).
31. Nakajima T, Maekita T, Oda I et al. Higher methylation levels in gastric mucosae significantly correlate with higher risk of gastric cancers. Cancer Epidemiol. Biomarkers Prev. 15(11), 2317-2321 (2006).
32. Marsit CJ, Koestler DC, Christensen BC, Karagas MR, Houseman EA, Kelsey KT. DNA methylation array analysis identifies profiles of blood-derived DNA methylation associated with bladder cancer. J. Clin. Oncol. 29(9), 1133-1139 (2011).
33. Wong EM, Southey MC, Fox SB et al. Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer. Cancer Prev. Res. (Phila). 4(1), 23-33 (2011).
34. Tahara T, Maegawa S, Chung W et al. Examination of whole blood DNA methylation as a potential risk marker for gastric cancer. Cancer. Prev. Res. (Phila). 6(10), 1093-1100 (2013).
35. Yuasa Y, Nagasaki H, Oze I et al. Insulin-like growth factor 2 hypomethylation of blood leukocyte DNA is associated with gastric cancer risk. Int. J. Cancer 131(11), 2596-2603 (2012).
36. Laird PW. The power and the promise of DNA methylation markers. Nat. Rev. Cancer 3(4), 253-266 (2003).
37. Suzuki H, Tokino T, Shinomura Y, Imai K, Toyota M. DNA methylation and cancer pathways in gastrointestinal tumors. Pharmacogenomics 9(12), 1917-1928 (2008).
38. Shen L, Toyota M, Kondo Y et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc. Natl Acad. Sci. USA 104(47), 18654-18659 (2007).
39. Ahn JB, Chung WB, Maeda O et al. DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer 117(9), 1847-1854 (2011).
40. Ogino S, Nosho K, Kirkner GJ et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 58(1), 90-96 (2009).
41. Hughes LA, Melotte V, de Schrijver J et al. The CpG island methylator phenotype: what's in a name? Cancer Res. 73(19), 5858-5868 (2013).
42. Toyota M, Ahuja N, Suzuki H et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res. 59(21), 5438-5442 (1999).
43. Kim H, Kim YH, Kim SE, Kim NG, Noh SH, Kim H. Concerted promoter hypermethylation of hMLH1, p16INK4A, and E-cadherin in gastric carcinomas with microsatellite instability. J. Pathol. 200(1), 23-31 (2003).
44. An C, Choi IS, Yao JC et al. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin. Cancer Res. 11(2 Pt 1), 656-663 (2005).
45. Enomoto S, Maekita T, Tsukamoto T et al. Lack of association between CpG island methylator phenotype in human gastric cancers and methylation in their background non-cancerous gastric mucosae. Cancer Sci. 98(12), 1853-1861 (2007).
46. Park SY, Kook MC, Kim YW et al. CpG island hypermethylator phenotype in gastric carcinoma and its clinicopathological features. Virchows Arch. 457(4), 415-422 (2010).
47. Chen HY, Zhu BH, Zhang CH et al. High CpG island methylator phenotype is associated with lymph node metastasis and prognosis in gastric cancer. Cancer Sci. 103(1), 73-79 (2012).
48. Zouridis H, Deng N, Ivanova T et al. Methylation subtypes and large-scale epigenetic alterations in gastric cancer. Sci. Transl. Med. 4(156), 156ra140 (2012).
49. Widschwendter M, Fiegl H, Egle D et al. Epigenetic stem cell signature in cancer. Nat. Genet. 39, 157-158 (2007).
50. Loh M, Liem N, Vaithilingam A et al. DNA methylation subgroups and the CpG island methylator phenotype in gastric cancer: a comprehensive profiling approach. BMC Gastroenterol. 14, 55 (2014).
51. Matsusaka K, Kaneda A, Nagae G et al. Classification of Epstein-Barr virus-positive gastric cancers by definition of DNA methylation epigenotypes. Cancer Res. 71(23), 7187-7197 (2011).
52. Noushmehr H, Weisenberger DJ, Diefes K et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17(5), 510-522 (2010).
53. Figueroa ME, Abdel-Wahab O, Lu C et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18(6), 553-567 (2010).
54. Tahara T, Yamamoto E, Madireddi P et al. Colorectal carcinomas with CpG island methylator phenotype 1 frequently contain mutations in chromatin regulators. Gastroenterology 146(2), 530-538.e5 (2014).
55. Wang K, Kan J, Yuen ST et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat. Genet. 43(12), 1219-1223 (2011).
56. Zang ZJ, Cutcutache I, Poon SL et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat. Genet. 44(5), 570-574 (2012).
57. Satoh A, Toyota M, Itoh F et al. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res. 63(24), 8606-8613 (2003).
58. Du W, Wang S, Zhou Q et al. ADAMTS9 is a functional tumor suppressor through inhibiting AKT/mTOR pathway and associated with poor survival in gastric cancer. Oncogene 32(28), 3319-3328 (2013).
59. Cheng AS, Li MS, Kang W et al. Helicobacter pylori causes epigenetic dysregulation of FOXD3 to promote gastric carcinogenesis. Gastroenterology 144(1), 122-133.e9 (2013).
60. Li X, Cheung KF, Ma X et al. Epigenetic inactivation of paired box gene 5, a novel tumor suppressor gene, through direct upregulation of p53 is associated with prognosis in gastric cancer patients. Oncogene 31(29), 3419-3430 (2012).
61. Weisenberger DJ, Siegmund KD, Campan M et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 38, 787-793 (2006).
62. Ogino S, Kawasaki T, Kirkner GJ, Kraft P, Loda M, Fuchs CS. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J. Mol. Diagn. 9, 305-314 (2007).
63. Zong L, Seto Y. CpG island methylator phenotype, Helicobacter pylori, Epstein-Barr virus, and microsatellite instability and prognosis in gastric cancer: a systematic review and meta-analysis. PLoS ONE 9(1), e86097 (2014).
64. Jover R, Nguyen TP, Perez-Carbonell L et al. 5-fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology 140(4), 1174-1181 (2011).
65. Wang M, Furuta T, Takashima M et al. Relation between interleukin-1beta messenger RNA in gastric fundic mucosa and gastric juice pH in patients infected with Helicobacter pylori. J. Gastroenterol. 34(Suppl. 11), 10-17 (1999).
66. Yamaoka Y, Kita M, Kodama T, Sawai N, Kashima K, Imanishi J. Induction of various cytokines and development of severe mucosal inflammation by cagA gene positive Helicobacter pylori strains. Gut 41(4), 442-451 (1997).
67. Kang GH, Shim YH, Jung HY, Kim WH, Ro JY, Rhyu MG. CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res. 61(7), 2847-2851 (2001).
68. Kang GH, Lee HJ et al. Aberrant CpG island hypermethylation of chronic gastritis, in relation to aging, gender, intestinal metaplasia, and chronic inflammation. Am. J. Pathol. 163(4), 1551-1556 (2003).
69. Li WQ, Pan KF, Zhang Y et al. RUNX3 methylation and expression associated with advanced precancerous gastric lesions in a Chinese population. Carcinogenesis 32(3), 406-410 (2011).
70. Kaise M, Yamasaki T, Yonezawa J, Miwa J, Ohta Y, Tajiri H. CpG island hypermethylation of tumor-suppressor genes in H. pylori-infected nonneoplastic gastric mucosa is linked with gastric cancer risk. Helicobacter 13(1), 35-41 (2008).
71. Yamashita M, Toyota M, Suzuki H et al. DNA methylation of interferon regulatory factors in gastric cancer and noncancerous gastric mucosae. Cancer Sci. 101(7), 1708-1716 (2010).
72. Yamamoto E, Toyota M, Suzuki H et al. LINE-1 hypomethylation is associated with increased CpG island methylation in Helicobacter pylori-related enlarged-fold gastritis. Cancer Epidemiol. Biomarkers Prev. 17(10), 2555-2564 (2008).
73. Suzuki H, Yamamoto E, Nojima M et al. Methylationassociated silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic field defect. Carcinogenesis 31(12), 2066-2073 (2010).
74. Meyer-ter-Vehn T, Covacci A, Kist M, Pahl HL. Helicobacter pylori activates mitogen-activated protein kinase cascades and induces expression of the proto-oncogenes c-fos and c-jun. J. Biol. Chem. 275(21), 16064-16072 (2000).
75. Issa JP, Ahuja N, Toyota M, Bronner MP, Brentnall TA. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res. 61(9), 3573-357 (2001).
76. Nishida N, Nagasaka T, Nishimura T, Ikai I, Boland CR, Goel A. Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology 47(3), 908-918 (2008).
77. Niwa T, Tsukamoto T, Toyoda T et al. Inflammatory processes triggered by Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells. Cancer Res. 70(4), 1430-1440 (2010).
78. Fukase K, Kato M, Kikuchi S et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 372(9636), 392-397 (2008).
79. Nakajima T, Enomoto S, Yamashita S et al. Persistence of a component of DNA methylation in gastric mucosae after Helicobacter pylori eradication. J. Gastroenterol. 45(1), 37-44 (2010).
80. Shin CM, Kim N, Park JH et al. Prediction of the risk for gastric cancer using candidate methylation markers in the non-neoplastic gastric mucosae. J. Pathol. 226(4), 654-665 (2012).
81. Ichikawa D, Koike H, Ikoma H et al. Detection of aberrant methylation as a tumor marker in serum of patients with gastric cancer. Anticancer Res. 24(4), 2477-2481 (2004).
82. Kolesnikova EV, Tamkovich SN, Bryzgunova OE et al. Circulating DNA in the blood of gastric cancer patients. Ann. NY Acad. Sci. 1137, 226-231 (2008).
83. Ikoma H, Ichikawa D, Daito I et al. Clinical application of methylation specific-polymerase chain reaction in serum of patients with gastric cancer. Hepatogastroenterology 54(75), 946-950 (2007).
84. Cheung KF, Lam CN, Wu K et al. Characterization of the gene structure, functional significance, and clinical application of RNF180, a novel gene in gastric cancer. Cancer 118(4), 947-959 (2012).
85. Yu QM, Wang XB, Luo J et al. CDH1 methylation in preoperative peritoneal washes is an independent prognostic factor for gastric cancer. J. Surg. Oncol. 106(6), 765-771 (2012).
86. Watanabe Y, Kim HS, Castoro RJ et al. Sensitive and specific detection of early gastric cancer with DNA methylation analysis of gastric washes. Gastroenterology 136(7), 2149-2158 (2009).
87. Oishi Y, Watanabe Y, Yoshida Y et al. Hypermethylation of Sox17 gene is useful as a molecular diagnostic application in early gastric cancer. Tumour Biol. 33(2), 383-393 (2012).
88. Christensen BC, Houseman EA, Marsit CJ et al. Aging and environmental exposures alter tissuespecific DNA methylation dependent upon CpG island context. PLoS Genet. 5(8), e1000602 (2009).
89. Teschendorff AE, Menon U, Gentry-Maharaj A et al. Agedependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res. 20(4), 440-446 (2012).
90. Hou L, Wang H, Sartori S et al. Blood leukocyte DNA hypomethylation and gastric cancer risk in a high-risk Polish population. Int. J. Cancer 127(8), 1866-1874 (2010).
91. Gao Y, Baccarelli A, Shu XO et al. Blood leukocyte Alu and LINE-1 methylation and gastric cancer risk in the Shanghai Women's Health Study. Br. J. Cancer 106(3), 585-591 (2012).